Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019163 (
hepatitis B
)
38,309
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The purpose of the present study was to measure the amount of antibody to
hepatitis B
core antigen (anti-HBc) in different populations by the immunoelectroosmophoresis method. High titers of anti-HBc, up to 1/4,096, were found in the acute stage of
hepatitis B
virus infections and in the chronic carrier state of
hepatitis B
surface antigen. In cases of acute hepatitis the anti-HBc titers gradually declined to low levels but persisted for the observation time of 5 to 6 years. Individuals positive for antibodies to
hepatitis B
surface and core antigens selected from a Swedish "normal" population showed still lower anti-HBc titers, indicating that the
hepatitis B
infection had occurred earlier. The anti-HBc titers in sera drawn at intervals of 4 years from a group of hemophilia patients may indicate previous infection with replicating
hepatitis B
virus rather than immunization with
noninfectious hepatitis
B core antigen material.
...
PMID:Persistence of serum antibody to hepatitis B core antigen. 90 43
Hepatitis A and
hepatitis B
are viral infections of the liver. Hepatitis A is spread by the fecal-oral route--i.e., by ingestion of virus shed in the stool of acutely infected individuals. The virus is transmitted from person to person or (in outbreaks) via contaminated food or water. Population groups at increased risk of acquiring hepatitis A include children and staff in day care centers.
Hepatitis B
is spread by blood and other body fluids from acutely infected individuals or chronically infected carriers. Infection occurs when virus contained in these fluids enters the body through mucosal surfaces or breaks in the skin. A vaccine against
hepatitis B
has been developed. It consists of
noninfectious hepatitis
B surface antigen purified from the plasma of chronic carriers. The three sequential inactivation treatments used in manufacture of the vaccine kill
hepatitis B
virus and other infectious agents that may be present in human plasma, including the human T cell-lymphotropic virus that causes the acquired immunodeficiency syndrome. The vaccine is well tolerated, highly immunogenic, and highly effective in preventing
hepatitis B
. Both live attenuated and killed vaccines against hepatitis A are also being investigated. A live attenuated vaccine is preferred and seems feasible on the basis of initial studies in animals and volunteers.
...
PMID:Development of vaccines against hepatitis A and hepatitis B. 301 91
